{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Baltimore&page=70&state=Maryland",
    "query": {
      "state": "Maryland",
      "city": "Baltimore",
      "page": 70
    },
    "page_size": 10
  },
  "pagination": {
    "page": 70,
    "page_size": 10,
    "total_count": 13759,
    "total_pages": 1376,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Baltimore&page=71&state=Maryland&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Baltimore&page=69&state=Maryland&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T20:26:38.954Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04451525",
      "title": "REal-World Analyses of Stroke - Thrombus Occlusion REtrieval",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Ischemic Stroke",
        "Vessel Occlusion",
        "Stroke",
        "Ischemic"
      ],
      "interventions": [
        {
          "name": "MicroVention Mechanical Thrombectomy Devices as first-line treatment",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Microvention-Terumo, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 710,
      "start_date": "2020-07-15",
      "completion_date": "2025-06-09",
      "has_results": false,
      "last_update_posted_date": "2025-06-18",
      "last_synced_at": "2026-11-20T20:26:38.954Z",
      "location_count": 37,
      "location_summary": "Burbank, California • Carmichael, California • Redwood City, California + 34 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04451525"
    },
    {
      "nct_id": "NCT07391774",
      "title": "Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Estrogen Receptor-Positive Breast Carcinoma",
        "HER2-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Oncotype DX Breast Cancer Assay",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ribociclib Succinate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1978,
      "start_date": "2026-08-10",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-20",
      "last_synced_at": "2026-11-20T20:26:38.954Z",
      "location_count": 260,
      "location_summary": "Jonesboro, Arkansas • Auburn, California • Berkeley, California + 216 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07391774"
    },
    {
      "nct_id": "NCT00493285",
      "title": "Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Viral Infections",
        "Respiratory Syncytial Virus Infections",
        "Parainfluenza Virus 3, Human"
      ],
      "interventions": [
        {
          "name": "MEDI-534",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "23 Months",
        "sex": "ALL",
        "summary": "6 Months to 23 Months"
      },
      "enrollment_count": 49,
      "start_date": "2007-07",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2012-07-19",
      "last_synced_at": "2026-11-20T20:26:38.954Z",
      "location_count": 30,
      "location_summary": "Conway, Arkansas • Little Rock, Arkansas • Aurora, Colorado + 25 more",
      "locations": [
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Palm Beach Gardens",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00493285"
    },
    {
      "nct_id": "NCT00546715",
      "title": "A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 95,
      "start_date": "2007-11",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2015-11-18",
      "last_synced_at": "2026-11-20T20:26:38.954Z",
      "location_count": 7,
      "location_summary": "Anaheim, California • Orlando, Florida • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Hamilton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546715"
    },
    {
      "nct_id": "NCT04359108",
      "title": "Environmental Localization Mapping and Guidance for Visual Prosthesis Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinitis Pigmentosa",
        "Visual Impairment",
        "Visual Prosthesis"
      ],
      "interventions": [
        {
          "name": "Navigation system mode: Argus Vision",
          "type": "DEVICE"
        },
        {
          "name": "Navigation system mode: Depth Vision",
          "type": "DEVICE"
        },
        {
          "name": "Navigation system mode: Depth Vision with Haptic / Audio",
          "type": "DEVICE"
        },
        {
          "name": "Navigation system mode: Haptic / Audio",
          "type": "DEVICE"
        },
        {
          "name": "Navigation system mode: High Field-of-View Depth Vision",
          "type": "DEVICE"
        },
        {
          "name": "Distance test vision mode: Low Resolution / Low Field-of-View",
          "type": "DEVICE"
        },
        {
          "name": "Distance test vision mode: Low Resolution / High Field-of-View",
          "type": "DEVICE"
        },
        {
          "name": "Distance test vision mode: High Resolution / Low Field-of-View",
          "type": "DEVICE"
        },
        {
          "name": "Distance test vision mode: High Resolution / High Field-of-View",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2021-03-16",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-11-20T20:26:38.954Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Laurel, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Laurel",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04359108"
    },
    {
      "nct_id": "NCT06556368",
      "title": "A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Tarcocimab tedromer",
          "type": "DRUG"
        },
        {
          "name": "Tabirafusp tedromer",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kodiak Sciences Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 667,
      "start_date": "2024-08-23",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-20T20:26:38.954Z",
      "location_count": 71,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06556368"
    },
    {
      "nct_id": "NCT05540860",
      "title": "A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Sevasemten Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Sevasemten Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Sevasemten Dose 3",
          "type": "DRUG"
        },
        {
          "name": "Sevasemten Dose 4",
          "type": "DRUG"
        },
        {
          "name": "Sevasemten Dose 5",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edgewise Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "9 Years",
        "sex": "MALE",
        "summary": "4 Years to 9 Years · Male only"
      },
      "enrollment_count": 76,
      "start_date": "2022-10-24",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-11-20T20:26:38.954Z",
      "location_count": 14,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05540860"
    },
    {
      "nct_id": "NCT04971785",
      "title": "Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Semaglutide (SEMA)",
          "type": "DRUG"
        },
        {
          "name": "Cilofexor (CILO)/Firsocostat (FIR)",
          "type": "DRUG"
        },
        {
          "name": "PTM SEMA",
          "type": "DRUG"
        },
        {
          "name": "PTM CILO/FIR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 457,
      "start_date": "2021-08-09",
      "completion_date": "2024-12-09",
      "has_results": true,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-11-20T20:26:38.954Z",
      "location_count": 175,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04971785"
    },
    {
      "nct_id": "NCT03810417",
      "title": "Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Digoxin Antibodies Fab Fragments",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Baseline EO > 360 pM",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "EO < 360 pM",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2019-07-22",
      "completion_date": "2024-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-11-20T20:26:38.954Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03810417"
    },
    {
      "nct_id": "NCT00261950",
      "title": "Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Sensipar (Cinacalcet HCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2006-05",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2014-07-21",
      "last_synced_at": "2026-11-20T20:26:38.954Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00261950"
    }
  ]
}